Original Contribution

Inflammatory Bowel Disease

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

  • The American Journal of Gastroenterology volume 113, pages 396403 (2018)
  • doi:10.1038/ajg.2017.501
  • Download Citation




The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNFα drugs in utero with that of children who were not exposed to the drugs.


Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNFα medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNFα agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan–Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring.


The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNFα agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8–1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5–4.3)).


In utero exposure to anti-TNFα drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

  • Subscribe to The American Journal of Gastroenterology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    , , . The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008;134:A69.

  2. 2.

    . Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010;16:881–895.

  3. 3.

    , , et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015;9:107–124.

  4. 4.

    , , et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150:e731.

  5. 5.

    , , et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis 2014;20:36–46.

  6. 6.

    , . Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013;108:1426–1438.

  7. 7.

    , , . Immunoglobulins—basic considerations. J Neurol 2006;253 (Suppl 5): V9–17.

  8. 8.

    , , et al. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology 1993;79:77–81.

  9. 9.

    , , et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151:110–119.

  10. 10.

    , , et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 2012;6:811–823.

  11. 11.

    , , et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053–1058.

  12. 12.

    , , et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.

  13. 13.

    , , et al. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS ONE 2015;10:e0129567.

  14. 14.

    , . [Hospital admissions for infectious diseases: 1999-2003 incidence in one health district in the autonomous community of Valencia, Spain]. Rev Esp Salud Publica 2007;81:411–420.

  15. 15.

    , , et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286–292 quiz e224.

  16. 16.

    , , et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut 2016;65:1261–1268.

  17. 17.

    , , et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis 2012;6:358–361.

  18. 18.

    , , et al. Association of B-1 B cells with follicular dendritic cells in spleen. J Immunol 2005;174:6918–6926.

  19. 19.

    , , . TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 2011;106:559–562.

  20. 20.

    , . Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol 2011;12:765–773.

  21. 21.

    , , et al. PIANO: a 1000 patients prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012;138:S149.

  22. 22.

    , , et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO Registry. Gastroenterology 2014;146:S1.

Download references


We thank the Clinical Committee (ClinCom) of the European Crohn and Colitis Organisation (ECCO) and the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) for their support in the study. In addition, we thank M. Ramas and A.G. McNicholl for programming the e-CRF in AEG-REDCap and T O’Boyle for the final English language revision funded by MSD.

Author information


  1. Gastroenterology Units Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

    • M Chaparro
    • , M J Casanova
    • , A Garre
    • , M G Donday
    •  & J P Gisbert
  2. Department of Gastroenterology and Department of Pediatric Gastroenterology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

    • A Verreth
  3. Hospital Universitari Germans Trias i Pujol and CIBEREHD, Badalona, Spain

    • T Lobaton
    •  & P Torres
  4. Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    • E Gravito-Soares
    •  & M Gravito-Soares
  5. Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

    • M Julsgaard
    •  & D Rudbeck-Resdal
  6. University of Padua, Padua, Italy

    • E Savarino
    •  & O Bartolo
  7. Centro Hospitalar São João, Porto, Portugal

    • F Magro
    •  & A Peixoto
  8. Gastroenterology Devision, Rabin Medical Center, Petach Tikva, Israel

    • I Avni Biron
    •  & G Martin
  9. Hospital Universitario Fundación Alcorcón, Alcorcón, Spain

    • P Lopez-Serrano
  10. Hospital Clinic and CIBEREHD, Barcelona, Spain

    • M Gompertz
  11. Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Lisboa, Portugal

    • S Vitor
  12. Hospital Clinico Universitario Lozano Blesa, IIS Aragon, CIBEREHD, Zaragoza, Spain

    • M Arroyo
  13. IBD Unit, Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Roma, Italy

    • D Pugliese
    •  & A Armuzzi
  14. Hospital Universitari Mutua de Terrassa and CIBEREHD, Terrassa, Spain

    • Y Zabana
  15. Hospital Universitario Miguel Servet, Zaragoza, Spain

    • R Vicente
  16. Hospital Universitario La Fe and CIBEREHD, Valencia, Spain

    • M Aguas
  17. Shaare Zedek Medical Center, Jerusalem, Israel

    • A Bar-Gil Shitrit
  18. Hospital General Universitario de Alicante and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Alicante, Spain

    • A Gutierrez
  19. St. Vincents University Hospital, Dublin, Ireland

    • G A Doherty
  20. Hospital Clinico Universitario de Valladolid, Valladolid, Spain

    • L Fernandez-Salazar
  21. Hospital Universitario Alvaro Cunqueiro, Vigo, Spain

    • J Martínez Cadilla
  22. Hospital General Universitario de Valencia, Valencia, Spain

    • J M Huguet
  23. Beaumont Hospital, Dublin, Ireland

    • A O'Toole
  24. IRCCS Saverio de Bellis, Castellana Grotte, Italy

    • E Stasi
  25. Hospital Universitario Infanta Sofia, Madrid, Spain

    • N Manceñido Marcos
  26. Hospital Universitari Parc Taulí.Institut d’Investigació i Innovació Parc Taulí. Departament de Medicina, Universitat Autònoma de Barcelona.CIBERehd, Instituto de Salud Carlos III, Sabadell, Spain

    • A Villoria
  27. Venizeleio General Hospital, Heraklion, Greece

    • K Karmiris
  28. CHU UCL Namur, Yvoir, Belgium

    • J F Rahier
  29. Complejo Universitario de Navarra, Pamplona, Spain

    • C Rodriguez
  30. Hospital Universitario A Coruña, Coruña, Spain

    • M Diz-Lois Palomares
  31. IBD Center, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy and Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy

    • G Fiorino
  32. Hospital Universitario Reina Sofia and IMIBIC, Córdoba, Spain

    • J M Benitez
  33. Azienda Policlinico Ospedaliero-Universitaria di Bari, Bari, Italy

    • M Principi
  34. Meir Hospital Kfar saba Tel Aviv University, Tel Aviv, Israel

    • T Naftali
  35. Hospital Clínico San Carlos and IdISSC, Madrid, Spain

    • C Taxonera
  36. Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens, Greece

    • G Mantzaris
  37. Azienda Ospedaliera “Pugliese-Ciaccio”, Catanzaro, Italy

    • L Sebkova
  38. Hospital de Clinicas, Montevideo, Uruguay

    • B Iade
  39. Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

    • D Lissner
  40. Hospital de Manises, Manises, Spain

    • I Ferrer Bradley
  41. Hospital Ramón y Cajal, Madrid, Spain

    • A Lopez-San Roman
  42. Hospital General Universitario Gregorio Marañón and IiSGM, Madrid, Spain

    • I Marin-Jimenez
  43. Hospital Universitario de Cruces, Baracaldo, Spain

    • O Merino
  44. Complejo Universitario de León, León, Spain

    • M Sierra
  45. Hospital de Torrejón, Torrejón de Ardoz, Spain

    • M Van Domselaar
  46. Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Policlinico di Milano AND Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

    • F Caprioli
  47. Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain

    • I Guerra
  48. Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal

    • P Peixe
  49. Consorci Sanitari de Terrasa, Terrasa, Spain

    • M Piqueras
  50. Hospital de Galdakao, Vizcaya, Spain

    • I Rodriguez-Lago
  51. Hospital San Jorge, Huesca, Spain

    • Y Ber
  52. Department of Paediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium

    • K van Hoeve
  53. Hospital Sant Joan de Deu, Barcelona, Spain

    • F J Martín de Carpi


  1. Search for M Chaparro in:

  2. Search for A Verreth in:

  3. Search for T Lobaton in:

  4. Search for E Gravito-Soares in:

  5. Search for M Julsgaard in:

  6. Search for E Savarino in:

  7. Search for F Magro in:

  8. Search for I Avni Biron in:

  9. Search for P Lopez-Serrano in:

  10. Search for M J Casanova in:

  11. Search for M Gompertz in:

  12. Search for S Vitor in:

  13. Search for M Arroyo in:

  14. Search for D Pugliese in:

  15. Search for Y Zabana in:

  16. Search for R Vicente in:

  17. Search for M Aguas in:

  18. Search for A Bar-Gil Shitrit in:

  19. Search for A Gutierrez in:

  20. Search for G A Doherty in:

  21. Search for L Fernandez-Salazar in:

  22. Search for J Martínez Cadilla in:

  23. Search for J M Huguet in:

  24. Search for A O'Toole in:

  25. Search for E Stasi in:

  26. Search for N Manceñido Marcos in:

  27. Search for A Villoria in:

  28. Search for K Karmiris in:

  29. Search for J F Rahier in:

  30. Search for C Rodriguez in:

  31. Search for M Diz-Lois Palomares in:

  32. Search for G Fiorino in:

  33. Search for J M Benitez in:

  34. Search for M Principi in:

  35. Search for T Naftali in:

  36. Search for C Taxonera in:

  37. Search for G Mantzaris in:

  38. Search for L Sebkova in:

  39. Search for B Iade in:

  40. Search for D Lissner in:

  41. Search for I Ferrer Bradley in:

  42. Search for A Lopez-San Roman in:

  43. Search for I Marin-Jimenez in:

  44. Search for O Merino in:

  45. Search for M Sierra in:

  46. Search for M Van Domselaar in:

  47. Search for F Caprioli in:

  48. Search for I Guerra in:

  49. Search for P Peixe in:

  50. Search for M Piqueras in:

  51. Search for I Rodriguez-Lago in:

  52. Search for Y Ber in:

  53. Search for K van Hoeve in:

  54. Search for P Torres in:

  55. Search for M Gravito-Soares in:

  56. Search for D Rudbeck-Resdal in:

  57. Search for O Bartolo in:

  58. Search for A Peixoto in:

  59. Search for G Martin in:

  60. Search for A Armuzzi in:

  61. Search for A Garre in:

  62. Search for M G Donday in:

  63. Search for F J Martín de Carpi in:

  64. Search for J P Gisbert in:

Competing interests

Guarantors of the article: M. Chaparro, MD, PhD, and J.P. Gisbert.

Specific author contributions: M.Chaparro and J.P. Gisbert: study design, data collection, data analysis, data interpretation, writing the manuscript. Rest of authors: patient inclusion and data collection. All authors approved the final version of the manuscript.

Financial support: This research has been funded by grant from the Instituto de Salud Carlos III (PI13/00041).

Potential competing interests: M. Chaparro has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, and Tillotts Pharma. M. Julsgaard has served as a speaker, compensated by MSD, Ferring, UCB, and Takeda, and has been on the advisory board for Janssen. J. Rahier: speaker fee—Abbvie, MSD, Takeda, Pfizer, Ferring, and Falk; consultancy—Abbvie, Takeda, Hospira, Mundipharma, MSD, Pfizer, and GlaxoSK; research grant—Takeda and Abbvie. C. Taxonera has served as a speaker, a consultant, and an advisory member for MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, and Gebro Pharma. G. Mantzaris has served as advisory board member for AbbVie, Astellas, Celgene, Danone, Ferring, Genesis, Hospira, Janssen, Millennium Pharmaceuticals, MSD, Otsuka, Pharmacosmos, Pfizer, Sandoz, Takeda, and UCB; speaker for AbbVie, Angelini, Astellas, Danone, Falk Pharma, Ferring, Galenica, Hospira, Janssen, MSD, Omega Pharma, and Takeda; consultant for MSD and Takeda, and has received research support AbbVie, Galenica, Genesis, Menarini Group, MSD, and Pharmathen. F. Caprioli served as consultant to Mundipharma, Abbvie, MSD, Takeda, Janssen, Roche, and Celgene. He received lecture fees from Abbvie, Ferring, Takeda, Allergy Therapeutics, and Janssen, and unrestricted research grants from Giuliani, Sofar, MS&D, Takeda, and Abbvie. I. Guerra has served as speaker for Pfizer, and consultant and advisory member for Kern Pharma. F.J. Martín de Carpi has received travel grants and lecture’s honorarium, and has served as consultant for Abbvie, MSD, Kern, and Celltrion. J.P. Gisbert has served as a speaker, a consultant, and an advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. A. Armuzzi has received consulting and/or advisory board fees from AbbVie, Allergan, Biogen, Celgene, Celltrion, Ferring, Hospira, Janssen, Lilly, MSD, Mundipharma, Pfizer, Samsung, Sofar, Takeda; lecture and/or speaker bureau fees from AbbVie, AstraZeneca, Chiesi, Ferring, Hospira, Janssen, MSD, Mitsubishi Tanabe, Mundipharma, Nikkiso, Pfizer, Otsuka, Samsung, Takeda, Tigenix, Zambon; research grant from MSD. G Fiorino served as a consultant and Advisory Board Member for MSD, AbbVie, Takeda, Janssen, Mundipharma, Sandoz, Pfizer. Donata Lissner received a research grant from Pfizer and lecture fees from Abbvie and Falk. A Verreth served as speaker for Takeda. The remaining authors declare no conflict of interest.

Corresponding author

Correspondence to M Chaparro.